Adverse Events and Real-World Outcomes of Intravenous Immunoglobulin in Dermatologic Diseases: A 20-Year Cohort Study

Clicks: 13
ID: 329031
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #223 of 245 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Intravenous immunoglobulin (IVIG) is widely used in dermatology for severe and refractory immune-mediated diseases; however, comprehensive real-world data regarding its effectiveness and safety across diverse dermatologic conditions remain limited. Objective To evaluate the clinical outcomes and adverse events associated with IVIG therapy in patients with dermatologic diseases treated in routine clinical practice. Methods A retrospective cohort study was conducted including 285 patients who received IVIG at a tertiary dermatology center between January 2001 and November 2021. Demographic characteristics, diagnoses, comorbidities, treatment responses, and immediate and delayed adverse events were analyzed. Results The majority of patients had autoimmune bullous diseases (61%). Favorable clinical outcomes were observed across disease groups, particularly in autoimmune bullous diseases and the Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) spectrum. Adverse events occurred in 44 patients (15.4%) and included both immediate and delayed reactions. Hypertension and flu-like symptoms were the most common immediate reactions, while renal impairment and thromboembolic events were the most significant delayed complications. Adverse events were not associated with the underlying dermatologic disease but were significantly more common in patients with comorbidities. Conclusion IVIG was associated with favorable clinical outcomes and was generally well tolerated in this retrospective cohort; however, careful assessment of patient comorbidities and individualized infusion strategies may help minimize treatment-related adverse events.
Reference Key
openalex_W7213521568 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kenan Aydoğan, C. Ünlü, Ferdi Öztürk, Hayriye Sarıcaoğlu, Emel Bülbül Başkan, Serkan Yazıcı
Are you one of these authors? Claim your profile
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag410
URL
https://doi.org/10.1093/ced/llag410
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.